Prognostic value of serum lactic dehydrogenase (S-LDH) in multiple myeloma |
| |
Authors: | B. SIMONSSON,G. BRENNING,C. KÄ LLANDER,A. Å HRE&dagger |
| |
Affiliation: | Department of Internal Medicine, University Hospital, Uppsala, Sweden. |
| |
Abstract: | Serum lactic dehydrogenase (S-LDH) was analysed at diagnosis in ninety-three patients with multiple myeloma. The patients were then followed up after a mean observation period of 39 months (SD 29). Serum lactic dehydrogenase was elevated in twenty-seven out of ninety-three patients and found to correlate with the serum concentrations of beta 2-microglobuline, creatinine, and thymidine kinase. In discriminant analysis of pretreatment S-LDH levels in relation to survival, the best discrimination level was 7.0 mukat 1(-1). Patients with values below 7 microkat 1(-1) ahd a median survival time of 45 months compared to 14 months for those with levels above 7 mukat 1(-1) (P less than 0.001). Serum lactic dehydrogenase at diagnosis, thus, has prognostic information in multiple myeloma. |
| |
Keywords: | Lactic dehydrogenase multiple myeloma prognosis |
|
|